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Introduction: Naked cuticle homolog 2 (NKD2) was found
to be frequently methylated in human breast and gastric
cancers. However, the epigenetic changes and mechanisms
of NKD2 in human esophageal cancer remain unclear.
Methods: Nine esophageal cancer cell lines and 154 cases of
primary esophageal cancer samples were analyzed using
methylation-speciﬁc polymerase chain reaction, immunohisto-
chemical analysis, Western blot, and xenograft mouse models.
Results: Loss of NKD2 expression and complete methylation
were found in KYSE150 and TE1 cells. Reduced NKD2
expression and partial methylation of the promoter region
were observed in KYSE30, KYSE70, KYSE410, KYSE140, and
COLO680 cells. High levels of NKD2 expression and unmethy-
lationwere detected inKYSE450 andTE8 cells. Reexpression of
NKD2 was induced by 5-aza-20-deoxycytidine in cells in which
NKD2 was not expressed or cells in which NKD2 expression
was reduced. NKD2 was methylated in 53.2% of human pri-
mary esophageal cancer samples (82 of 154), and promoter
region hypermethylation was signiﬁcantly associated with
reduced expression of NKD2 (p< 0.01).NKD2methylationwas
associated with tumor, node, and metastasis stage and lymph
node metastasis (p < 0.01). Our results suggest that NKD2 is
regulated by promoter region methylation and that methyl-
ation of NKD2may serve as a prognostic marker in esophageal
cancer. Our further studies demonstrate that NKD2 suppresses
cell proliferation, colony formation, cell invasion, andmigration
and also induces G1/S checkpoint arrest in esophageal cancer
cells. NKD2 suppressed xenograft tumor growth and inhibited
Wnt signaling in human esophageal cancer cells.Journal of Thoracic Oncology Vol. 11 No. 11: 1912-1926Conclusions: NKD2 is frequently methylated in human
esophageal cancer, and the expression of NKD2 is regulated
by promoter region methylation. NKD2 suppresses esoph-
ageal cancer progression by inhibiting Wnt signaling both
in vitro and in vivo.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Esophageal cancer is the eighth most common cancer
and the sixth leading cause of cancer-related death
November 2016 NKD2 Inhibits Wnt Signaling in ESCC 1913worldwide.1 The overall 5-year survival remains less than
15%.2 Poor outcomes in patients with esophageal cancer
are related to diagnosis at advanced (metastatic) stages
and the propensity for metastases.3 Esophageal squa-
mous cell carcinoma (ESCC) is the predominant histo-
logical type of esophageal carcinoma worldwide.4
Tobacco use and alcohol consumption are risk factors
for development of ESCC, and the combination of tobacco
and alcohol consumption further increases the risk for
development of ESCC. Mutations in enzymes that
metabolize alcohol have been associated with increased
risk for development of ESCC.5–7 Genomewide association
analysis has demonstrated that gene-environment inter-
action promotes development of ESCC.8 Other studies
have found that a second cancer develops in 2% of pa-
tients with esophageal cancer and 11% of patients with
head and neck cancer on account of ﬁeld cancer-
ization.9,10 These studies support the idea that environ-
ment plays an important role in ESCC. Genetic and
epigenetic alterations are involved in esophageal carci-
nogenesis.11 Whole genome and whole exome sequencing
in Chinese patients with ESCC revealed eight mutated
genes, including six known tumor-associated genes (tu-
mor protein p53 gene [TP53], RB transcriptional core-
pressor 1 gene [RB1], cyclin-dependent kinase 2 gene
[CDKN2A], phosphatidylinositol 4,5-bisphosphate 3-
kinase catalytic subunit alpha gene [PIK3CA], Homo sa-
piens notch 1[NOTCH1], and nuclear factor erythroid 2,
like 2 gene [NFE2L2]) and two novel genes (ADAM met-
allopeptidase domain 29 gene [ADAM29] and family with
sequence similarity 135 member B gene [FAM135B]).12
Additional genes were found to be frequently methyl-
ated in ESCC in previous studies.13–24 Aberrant expres-
sion levels of Wnt signaling pathway components are
found in many types of cancers, including esophageal
cancer, and the Wnt signaling pathway plays an impor-
tant role in cancer progression.17,25
Despite recent advances in treatment strategies for
esophageal cancer, there has been no signiﬁcant
improvement in overall survival rate for advanced and
metastatic disease.26 New strategies are necessary for
early detection and to improve treatment options in
ESCC. Aberrant epigenetic changes can be induced by
environmental factors, and epigenetic changes are
reversible under certain circumstances.27,28 Therefore,
more effective therapeutic strategies based on epige-
netics are being developed.
The naked cuticle (NKD) family includes Drosophila
naked cuticle and its two vertebrate orthologs, naked
cuticle homolog 1 (NKD1) and naked cuticle homolog 2
(NKD2). NKD1 is located in human chromosome 16q12.1,
which has frequent loss of heterozygosity in human breast
and hepatocellular carcinoma.29,30 NKD2 is located in
chromosome 5p15.3. Loss of heterozygosity has beenfrequently found in these regions in multiple tumors.31–33
In both zebraﬁsh and mice, NKD inhibits canonical and
noncanonical Wnt signaling.34–36 The C-terminus of NKD2
is highly disordered, whereas the N-terminal region con-
tains most of the functional domains, including myr-
istoylation, an EF-hand motif, a Dishevelled binding
region, and a vesicle recognition and membrane targeting
motif.37–39 NKD2 binds to multiple proteins and may
function as a switch protein through its several functional
motifs.40 Both NKD1 and NKD2 have been proposed to
interact with Dishevelled through their EF-hand–like
motif. In addition, NKD2 has been reported to bind to
Dishevelled through its transforming growth factor-a
binding region.39,40 NKD2was reported to suppress tumor
growth and metastasis in osteosarcoma through negative
regulation of Wnt signaling.41 Our previous study found
that methylation of NKD2 promotes breast cancer growth
by activating Wnt signaling.42 The methylation status and
the function of NKD2 in esophageal cancer have yet to be
elucidated. Therefore, we investigated the epigenetic
changes and functions of NKD2 in human ESCC.
Materials and Methods
Human Tissue Samples and Cell Lines
Fifteen samples of human normal esophageal mucosa
and samples from 154 cases of human esophageal cancer
were collected from the Chinese People’s Liberation
Army (PLA) General Hospital in Beijing. The median age
of the cancer patients was 62.1 years (range 46–87), and
the ratio of male to female patients was 3.05:1. All cancer
samples were classiﬁed according to tumor, node, and
metastasis (TNM) staging (American Joint Committee on
Cancer, 2010), including ﬁve cases of stage I, 99 cases of
stage II, and 50 cases of stage III cancer. All samples
were collected following the guidelines approved by the
Institutional Review Board of the Chinese PLA General
Hospital with written informed consent from patients
(Reference No. 20090701-015).
Nine esophageal cancer cell lines (KYSE450, KYSE30,
KYSE150, KESE70, TE8, KYSE410, TE1, KYSE140, and
COLO680) were previously established from primary
esophageal cancer and maintained in 90% Roswell Park
Memorial Institute 1640 medium (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum.
5-AZA Treatment
Esophageal cancer cell lines were split in a low-
density conﬂuence (30%) 12 hours before treatment.
Cells were treated with 5-aza-20-deoxycytidine (5-AZA
[Sigma, St. Louis, MO]) at a concentration of 2 mM.
Growth medium conditioned with 5-AZA at a concen-
tration of 2 mM was exchanged every 24 hours for a total
of 96 hours of treatment.
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Transcriptase PCR
Total RNA was isolated by Trizol reagent (Life
Technologies, Carlsbad, CA). First-strand cDNA was
synthesized according to the manufacturer’s instructions
(Invitrogen, Carlsbad, CA). The polymerase chain
reaction (PCR) primers used for NKD2 were 50-ACAGGA
GGTTGTCTGCACACG-30 (F) and 50-GACTTGAGGAACTGC
TTCTCC-30 (R). The primer sets for NKD2 were designed
to span intronic sequences between adjacent exons to
control for genomic DNA contamination. Semi-
quantitative reverse-transcriptase PCR (RT-PCR) was
ampliﬁed for 33 cycles. Glyceraldehyde-3-phosphate
dehydrogenase was used as an internal control.Mutation Detection, Bisulﬁte Modiﬁcation, MSP,
and BSSQ
DNA was prepared by the proteinase K method. To
detect NKD2 mutations (72C>T, 1231G>T, and
689C>T) in nine esophageal cancer cell lines and 154
cases of primary ESCC, the following sequencing primers
were used: NKD2-72C-T- F: CACGGCGCGTCTCTTTCC,
NKD2-72C-T- R: TACCCGCCACTCAGCATG, NKD2-689C-
T-F: AGGGAGTTCACAGGGTTCT, NKD2-689C-T-R: AGGTC
CAGGTAGTGGTTTCT, NKD2 1231G-T-F: GCAGCAAGTC
CGGGAAAGC, and NKD2 1231G-T-R: GCTAGGACGGGTG
GAAGTG. Bisulﬁte treatment was carried out as previ-
ously described.43,44 Methylation-speciﬁc PCR (MSP)
primers were designed according to genomic sequences
around transcription start sites and synthesized to
detect unmethylated and methylated alleles. Bisulﬁte
sequencing (BSSQ) was performed as previously
described.17 BSSQ products were ampliﬁed by primers
ﬂanking the targeted regions and included MSP prod-
ucts. The locations and the sequences of BSSQ and MSP
primers were listed in Supplementary Table 1 and
shown in Supplementary Figure 1. To obtain more evi-
dence supporting our discovery, the expression of NKD2
and the methylation status in The Cancer Genome Atlas
database were analyzed by the Pearson correlation
method in esophageal cancer and adjacent tissue sam-
ples (Supplementary Figs. 2 and 3).IHC Analysis
Immunohistochemical (IHC) analysis was performed
in human esophageal cancer samples and paired adja-
cent tissue samples. The NKD2 antibody (Novus Bi-
ologicals, Littleton, CO), matrix metalloproteinase 2
(MMP2) antibody (Proteintech, Chicago, IL), matrix
metalloproteinase 9 (MMP9) antibody (Proteintech),
phosphorylated b-catenin (p-b-catenin) antibody
(Bioworld Technology Inc., St. Louis Park, MN), and total
b-catenin antibody (Cell Signaling Technology, Danvers,MA) were diluted to 1:500, 1:200, 1:200, 1:100, and
1:200, respectively. For antigen retrieval, the slides were
placed in citrate antigen-repairing solution and heated in
a high-pressure cooker until steam arose. The slides
were kept inside the cooker for 150 seconds and then
cooled at room temperature for 15 minutes. The staining
intensity and extent of the staining area were scored
using the German semiquantitative scoring system as
described previously.18,45
Plasmid Construction
Human full-length NKD2 coding DNA sequence
(GenBank accession number NM_033120) was ampliﬁed
and subcloned as described previously42 using the
following primers: 50-GAGGATCCGCCACCATGGGGAAA
CTGCAGTCGAAG-30 (F) and 50-GATCTCGAGCTAGGA
CGGGTGGAAGTGGT-30 (R). NKD2 expressing lentiviral or
empty vectors was packaged using the ViraPower lenti-
viral expression system (Invitrogen, San Diego, CA).
Lentivirus was added to the growing medium of
KYSE150 and TE1 cells, and cells stably expressed by
NKD2 were selected using blasticidin (Invitrogen, San
Diego) at a concentration of 2 mg/mL.
Cell Viability Detection
Cells were plated into 96-well plates at a density of
2  103 cells per well, and cell viability was measured by
the methyl thiazolyl tetrazolium assay (KeyGEN Biotech,
Nanjing, People’s Republic of China) at 0, 24, 48, and 72
hours. Absorbance was measured on a microplate reader
(Thermo Multiskan MK3 [Thermo Fisher Scientiﬁc,
Danvers, MA]) at a wavelength of 490 nm.
Colony Formation Assay
Cells in which NKD2 was unexpressed or stably
expressed were seeded at 500 cells per well in six-well
culture plates in triplicate. The complete growth me-
dium conditioned with blasticidin at 2 ug/mL was
exchanged every 72 hours. After 2 weeks, cells were
ﬁxed with 75% ethanol for 30 minutes and stained with
0.2% crystal violet (Beyotime, Nanjing, China) for visu-
alization and counting.
Flow Cytometry
KYSE150 and TE1 cells in which NKD2 was unex-
pressed and reexpressed were starved 12 hours for syn-
chronization, and the cells were restimulated with 10%
fetal bovine serum for 24 hours. Cells were ﬁxedwith 70%
ethanol and treated using the Cell Cycle Detection Kit
(KeyGEN Biotech). The cells were then sorted by a FACS-
Caliber ﬂow cytometer (BD Biosciences, Mansﬁeld, MA).
The cell phase distribution was analyzed by Modﬁt soft-
ware (Verity Software House, Topsham, ME).
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KYSE150 and TE1 cells in which NKD2 was unex-
pressed and reexpressed were suspended in serum-free
medium. Cells (2  105) were placed into the upper
chamber of an 8-mm pore size transwell apparatus
(Corning, Corning, NY) and incubated for 20 hours. Cells
that migrated to the lower surface of the membrane
were stained with crystal violet and counted in three
independent high-power ﬁelds (200). For invasion
analysis, KYSE150 and TE1 cells in which NKD2 was
unexpressed and reexpressed (2  105) were seeded
into the upper chamber of a transwell apparatus coated
with extracellular matrix (ECM) gel (BD Biosciences, San
Jose, CA) and incubated for 36 hours. Cells that invaded
the lower membrane surface were stained with crystal
violet and counted in three independent high-power
ﬁelds (200).
SiRNA Knockdown Technique
Selected small interfering RNAs (siRNAs) targeting
NKD2 and the RNAi negative control duplex were used
in this study. The sequences of the siRNAs targeting
NKD2 and the RNAi negative control were as follows:
NKD2-F: 50-GGGAUUGAGAACUACACGUTT-30 and NKD2-
R: 50-ACGUGUAGUUCUCAAUCCCTT-30; negative control-
F: 50-UUCUCCGAACGUGUCACGUTT-30 and negative
control-R: 50-ACGUGACACGUUCGGAGAATT-30. The RNAi
oligonucleotide and RNAi negative control duplex were
transfected into KYSE450 cells, which expressed high
levels of NKD2.
Esophageal Cancer Cell Xenograft Mouse Model
KYSE150 cells (4106 cells in 0.1 mL phosphate-
buffered saline) in which NKD2 was stably expressed and
unexpressed were subcutaneously injected into the dorsal
ﬂank of 5-week-old female BALB/c nude mice. The tumor
sizes were measured every 3 days from the third day after
implantation for 24 days. KYSE450 cells (4  106 cells in
0.1 mL phosphate-buffered saline), in which NKD2 was
either highly expressed or knocked down, were subcuta-
neously injected into the dorsal ﬂank of 5-week-old female
BALB/c nude mice. As KYSE450 cells grow slowly, the
tumor sizes were measured every 4 days from the fourth
day after implantation for 24 days. The tumor volumes
were calculated according to the following formula:
V ¼ L  W2/2, where V is the volume (mm3), L is the
largest diameter (mm), and W is the smallest diameter
(mm). All procedures were approved by the Animal Ethics
Committee of the Chinese PLA General Hospital.
Western Blot
Protein samples from esophageal cancer cells were
collected and Western blot was performed as describedpreviously.46 Antibodies were diluted according to
manufacturer’s instructions. The primary antibodies
were as follows: NKD2 (Cell Signaling Technology),
MMP2, matrix metalloproteinase 7 (MMP7), MMP9,
cyclin D1, c-myc, p-b-catenin, b-catenin, and b-actin
(Bioworld Technology).
Statistical Analysis
SPSS 17.0 software (IBM, Armonk, NY) was used for
data analysis. All data are presented as means plus or
minus SD and analyzed using the Student’s t test. The chi-
square test and the Fisher’s exact test were used to
analyze the association between NKD2methylation status
and clinicopathologic factors and the association between
NKD2 expression and methylation status. Correlations
between NKD2 and MMP2, MMP9, and p-b-catenin were
analyzed using Pearson’s correlation coefﬁcient. A p value
less than 0.05 was considered statistically signiﬁcant.
Results
NKD2 Expression Is Regulated by Promoter
Region Methylation in Esophageal Cancer Cell
Lines
No mutations were found in the naked cuticle homo-
log 2 gene (NKD2) gene in human ESCC cell lines and
primary tissue samples. The expression of NKD2 was
detected by semiquantitative RT-PCR in human esopha-
geal cancer cell lines. As shown in Figure 1A, loss of NKD2
expression was found in KYSE150 and TE1 cells. Reduced
expression of NKD2 was observed in KYSE30, KYSE70,
KYSE410, KYSE140, and COLO680 cells. High-level
expression of NKD2 was detected in KYSE450 and TE8
cells. The methylation status of the NKD2 promoter was
examined by MSP. Complete methylation was found in
KYSE150 and TE1 cells. Partial methylation was detected
in KYSE30, KYSE70, KYSE410, KYSE140, and COLO680
cells. Unmethylation was observed in KYSE450 and TE8
cells (Fig. 1B). These results demonstrate that loss or
reduced expression of NKD2 was correlated with pro-
moter region methylation in human esophageal cancer
cells. To further reveal the methylation density and vali-
date the MSP results, the BSSQ technique was used. As
shown in Figure 1C, NKD2 was completely methylated in
KYSE150 and TE1 cells, partially methylated in KYSE410
cells, and unmethylated in KYSE450 cells and normal
esophageal mucosa. These results are consistent with the
MSP results (Fig. 1C). To further analyze whether NKD2
expression is regulated by promoter region methylation,
KYSE450, KYSE30, KYSE150, KYSE70, TE8, KYSE410,
TE1, KYSE140, and COLO680 cells were treated with 5-
AZA, a demethylating reagent. Restoration of NKD2
expression was induced by 5-AZA in KYSE150 and TE1
cells. Increased expression of NKD2 was observed in
Figure 1. The expression and methylation status of naked cuticle homolog 2 (NKD2) in esophageal cancer cells and normal
esophageal mucosa (NE). (A) Semiquantitative reverse-transcriptase polymerase chain reaction (RT-PCR) shows NKD2
expression levels in esophageal cancer cell lines. KYSE450, KYSE30, KYSE150, KESE70, TE8, KYSE410, TE1, KYSE140, and
COLO680 are esophageal cancer cell lines. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is the internal control of RT-
PCR. H2O is double-distilled water. Minus sign indicates absence of 5-aza-20-deoxycytidine (5-AZA) and plus sign indicates
presence of 5-AZA. (B) Methylation-speciﬁc polymerase chain reaction (MSP) results of NKD2 in esophageal cancer cell lines.
U refers to unmethylated alleles, and M refers to methylated alleles. In vitro methylated DNA (IVD) serves as a methylation
control; normal peripheral lymphocyte DNA (NL) serves as an unmethylation control. H2O is double-distilled water. (C)
Bisulﬁte sequencing (BSSQ) results of NKD2. KYSE150, KYSE410, TE1, and KYSE450 are esophageal cancer cells. Double-
headed arrow indicaets that the MSP PCR product spanned 103 base pairs (bp) in NKD2. Bisulﬁte sequencing focused on a
287-bp region of the CpG island (–287 bp to þ38 bp) across the NKD2 transcription start site (TSS). Filled circles are
methylated CpG sites, and open circles are unmethylated CpG sites.
1916 Cao et al Journal of Thoracic Oncology Vol. 11 No. 11KYSE30, KYSE70, KYSE410, KYSE140, and COLO680 cells
treated with 5-AZA, whereas no expression changes were
found in KYSE450 and TE8 cells before and after 5-AZA
treatment (Fig. 1A). These results suggest that the
expression of NKD2 is regulated by promoter region
methylation in human esophageal cancer cells.NKD2 Is Frequently Methylated in Primary
Human Esophageal Cancer
To further explore the methylation status of NKD2 in
primary human esophageal cancer, the methylation sta-
tus was examined by MSP in tissue samples from 154
cases of esophageal cancer and 15 samples of normal
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was methylated in 53.2% of primary esophageal cancer
samples (82 of 154), and no methylation was detected in
normal esophageal mucosa (Fig. 2A and B). As shown in
Table 1, NKD2 methylation was signiﬁcantly associated
with TNM stage and lymph node metastasis (both
p < 0.01), but no association was found between NKD2Figure 2. Methylation status and expression of naked cuticle h
Methylation-speciﬁc polymerase chain reaction (MSP) results of
results of MSP for NKD2 in primary esophageal cancer samples (E
showing NKD2 expression in esophageal cancer and match
images: 400). (D) NKD2 expression scores are shown as box pl
bottom and top of the boxes represent the 25th and 75th perce
data. The expression level of NKD2 was signiﬁcantly different be
0.001). (E) The bar diagram shows the expression and DNA met
expression of NKD2 was signiﬁcantly associated with promotermethylation and age, sex, tumor size, or differentiation
(all p > 0.05). To further validate that NKD2 expression
is regulated by promoter region methylation, 30 cases of
available matched esophageal cancer and adjacent tissue
parafﬁn samples were evaluated by IHC analysis. NKD2
staining was observed mainly in the cytoplasm of the
esophagus. NKD2 is highly expressed in adjacent tissueomolog 2 (NKD2) in primary esophageal cancer samples. (A)
NKD2 in normal esophageal mucosa (NE). (B) Representative
C). (C) Representative immunohistochemical analysis results
ed adjacent tissue samples (upper images: 100; lower
ots, with horizontal lines representing the median score; the
ntiles, respectively, and vertical bars represent the range of
tween adjacent tissue and esophageal cancer samples (***p <
hylation status of NKD2 in different cancer samples. Reduced
region methylation (**p < 0.01).
Table 1. Clinical Factors and NKD2 Methylation in 154 Cases of Esophageal Cancer
Clinical Factor n
NKD2 Methylation Status
p Value
Methylated
n ¼ 82 (53.2%)
Unmethylated
n ¼ 72 (46.8%)
Age, y
<50 10 5 5 p ¼ 1.0
50 144 77 67
Sex
Male 116 65 51 p ¼ 0.23
Female 38 17 21
Tumor size, cm
<5 99 50 49 p ¼ 0.36
5 55 32 23
Differentiation
Well 9 6 3 p ¼ 0.38
Moderate 97 54 43
Poor 48 22 26
TNM stage
Ⅰ þ Ⅱ 104 47 57 p < 0.01
Ⅲ þ Ⅳ 50 35 15
Lymph node metastasis
N0 90 39 51 p < 0.01
N1 64 43 21
Note: p Values are obtained from chi-square test and Fisher’s exact test; p less than 0.05 indicates a signiﬁcant difference.
NKD2, naked cuticle homolog 2; TNM, tumor, node, and metastasis.
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(Fig. 2C and D). Reduced expression of NKD2 is associ-
ated with promoter region hypermethylation (p < 0.01
[Fig. 2E]). These results demonstrate that NKD2 is
regulated by promoter region methylation in primary
esophageal cancer.
Restoration of NKD2 Expression Suppresses Cell
Proliferation and Induces G1/S Arrest in
Esophageal Cancer Cells
To evaluate the effects of NKD2 on cell prolifera-
tion, cell viability was detected by methyl thiazolyl
tetrazolium and colony formation assays. The optical
density values were 0.892 ± 0.027 versus 0.763 ±
0.024 (p < 0.05) in KYSE150 cells and 0.551 ± 0.024
versus 0.438 ± 0.011 (p < 0.001) in TE1 cells before
and after restoration of NKD2 expression (Fig. 3A). The
results demonstrated that NKD2 inhibited esophageal
cancer cell viability. The effect of NKD2 on cell pro-
liferation was evaluated by colony formation assays.
The clone numbers were 135.3 ± 6.8 versus 57.7 ± 4.0
(p <0.001) in KYSE150 cells and 58.3 ± 4.7 versus
29.7 ± 3.5 (p <0.001) in TE1 cells before and after
restoration of NKD2 expression (Fig. 3B). These results
suggest that NKD2 suppresses esophageal cancer cell
growth.
To further understand the mechanism of NKD2 in
development of esophageal cancer, the role of NKD2 inthe cell cycle was analyzed by ﬂow cytometry. In
KYSE150 cells, the cell phase distributions before and
after reexpression of NKD2 were as follows: G0/1 phase:
33.46 ± 0.58% versus 41.82 ± 1.73%; S phase: 46.17 ±
2.21% versus 37.15 ± 1.46%; and G2/M phase: 20.37 ±
2.21% versus 21.03 ± 0.31%. The percentage of cells in
G0/1 phase increased signiﬁcantly whereas the per-
centage of cells in S phase decreased signiﬁcantly after
reexpression of NKD2 (all p < 0.01).
In TE1 cells, the cell phase distributions before and
after reexpression of NKD2 were as follows: G0/1 phase:
44.13 ± 2.60% versus 61.73 ± 1.28%; S phase: 44.21 ±
3.88% versus 22.93 ± 1.77%; and G2/M phase: 11.67 ±
1.38% versus 15.34 ± 0.82% (Fig. 3C). The percentage of
cells in G0/1 phase increased whereas the percentage of
cells in S phase decreased signiﬁcantly after reex-
pression of NKD2 in TE1 cells (all p < 0.001). These
results suggest that NKD2 induced G1/S checkpoint ar-
rest in esophageal cancer cells.
Restoration of NKD2 Expression Inhibits Cell
Migration and Invasion in Human Esophageal
Cancer Cells
The transwell assay was performed in the absence of
ECM gel coating to explore the effects of NKD2 on cell
migration. The numbers of migrated cells for each high-
power ﬁeld under the microscope were 105.7 ± 5.1
versus 63.0 ± 4.0 in KYSE150 cells and 147 .0 ± 6.6
Figure 3. Naked cuticle homolog 2 (NKD2) inhibits esophageal cancer cell proliferation. (A) Growth curves represent the cell
viability analyzed by the methyl thiazolyl tetrazolium assay in KYSE150 and TE1 cells in which NKD2 was reexpressed and
unexpressed. The experiments were performed in triplicate (*p< 0.05 and ***p< 0.001). (B) Colony formation results show that
colony number was reduced by reexpression of NKD2 in KYSE150 and TE1 cells. Each experiment was repeated three times. The
average number of tumor clones is represented by a bar diagram (***p< 0.001). (C) Cell phase distribution in KYSE150 and TE1
cells in which NKD2 was unexpressed and reexpressed. The ratio is presented by a bar diagram. Each experiment was repeated
three times (**p < 0.01 and ***p < 0.001). G0/G1, G0/G1 phase; S, S phase; G2/M, G2/M phase.
November 2016 NKD2 Inhibits Wnt Signaling in ESCC 1919versus 52.3 ± 5.7 in TE1 cells before and after restora-
tion of NKD2 expression. The cell numbers were reduced
signiﬁcantly after reexpression of NKD2 in esophageal
cancer cells (all p < 0.001, Fig. 4A). These resultsdemonstrate that NKD2 inhibits esophageal cancer cell
migration.
Next, the transwell assay with ECM coating was
used to evaluate the effects of NKD2 on cell invasion.
Figure 4. Restoration of naked cuticle homolog 2 (NKD2) expression inhibits cell migration and invasion. (A) Cell migration
in KYSE150 and TE1 cells in which NKD2 was unexpressed and reexpressed. The ratio is presented by a bar diagram. Each
experiment was repeated three times (***p < 0.001). (B) Cell invasion in KYSE150 and TE1 cells in which NKD2 was un-
expressed and reexpressed. The ratio is presented by a bar diagram. Each experiment was repeated three times (***p <
0.001). (C) The expression levels of NKD2, matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-7 (MMP-7), and
matrix metalloproteinase-9 (MMP-9) were detected by Western blot in KYSE150 and TE1 cells in which NKD2 was unex-
pressed and reexpressed. Knockdown of NKD2 by small interfering RNA (siRNA) was performed to validate the results in
KYSE450 cells in which NKD2 was highly expressed. (D) Representative images of immunohistochemical analysis for NKD2,
MMP2, and MMP9 in human esophageal squamous cell cancer. The expression levels of NKD2, MMP2, and MMP9 were
evaluated by the German semiquantitative scoring system. The correlation of NKD2 and MMP2, or NKD2 and MMP9, was
analyzed by Pearson correlation coefﬁcient. The x axis represents levels of NKD2 and the y axis represents levels of MMP2
or MMP9. NC, KYSE450 cells in which NKD2 is highly expressed; SiNKD2, KYSE450 cells in which NKD2 is knocked down by
siRNA.
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ﬁeld under the microscope were 114.7 ± 4.5 versus
79.7 ± 4.5 in KYSE150 cells and 137.0 ± 4.0 versus
65.0 ± 2.7 in TE1 cells before and after restoration of
NKD2 expression. The cell numbers were reduced
signiﬁcantly after reexpression of NKD2 in KYSE150and TE1 cells (all p < 0.001 [Fig. 4B]). These results
suggest that NKD2 impedes esophageal cancer cell
invasion.
To further understand the mechanism of NKD2 in
esophageal cancer migration and invasion, the expression
levels of MMP2, MMP7, and MMP9 were detected by
November 2016 NKD2 Inhibits Wnt Signaling in ESCC 1921Western blot. As shown in Figure 4C, the expression levels
of MMP2, MMP7, and MMP9 were reduced after reex-
pression of NKD2 in KYSE150 and TE1 cells. The inhibi-
tory role of NKD2 on MMP2, MMP7, and MMP9
expression was further validated by knockdown of NKD2
in KYSE450 cells. Taken together, the aforementioned
results suggest that NKD2 suppresses esophageal cancer
cell migration and invasion. The expression levels of
MMP2 and MMP9 in 30 cases of available human esoph-
ageal cancer samples were evaluated by IHC analysis. As
shown in Figure 4D, the expression levels of MMP2 and
MMP9 were negatively correlated with the expression
levels of NKD2 in human esophageal cancer, with corre-
lation coefﬁcients of –0.417 (p < 0.05) and –0.618 (p <
0.001), respectively.Figure 5. Naked cuticle homolog 2 (NKD2) inhibits canonical
expression levels of b-catenin, cyclin D1, and c-myc were
catenin) increased after reexpression of NKD2 in KYSE150 and
expression levels of b-catenin, c-myc, and cyclin D1 increased
in KYSE450 cells. (C) Representative images of immunohisto
(p-b-catenin) in human esophageal squamous cell cancer. The
by the German semiquantitative scoring system. The correla
correlation coefﬁcient. The x axis represents levels of NKD2, a
cells in which NKD2 is highly expressed; SiNKD2, KYSE450 ceNKD2 Inhibits Wnt/b-Catenin Signaling in
Esophageal Cancer
NKD2 has been reported to negatively regulate ca-
nonical Wnt signaling in multiple tumors.41,42 To deter-
mine whether the canonical Wnt signaling pathway is
regulated by NKD2 in human esophageal cancer, key
downstream components of the Wnt signaling pathway
were detected by Western blotting. The level of b-
catenin was reduced and the level of phospho-b-catenin
was increased after reexpression of NKD2 in KYSE150
and TE1 cells. The expression levels of the Wnt signaling
targeting-genes, homo sapiens C-MYC proto-oncogene (c-
myc), and homo sapiens cyclin D1 (CCND1, cyclin D1),
were reduced after reexpression of NKD2 in KYSE150
and TE1 cells (Fig. 5A). These results demonstrate thatWnt signaling in human esophageal cancer cells. (A) The
reduced, and the level of phosphorylated b-catenin (p-b-
TE1 cells. (B) The level of p-b-catenin was reduced and the
after knockdown of NKD2 by small interfering RNA (siRNA)
chemical analysis for NKD2 and phosphorylated b-catenin
expression levels of NKD2 and p-b-catenin were evaluated
tion of NKD2 and p-b-catenin was analyzed with Pearson’s
nd the y axis represents levels of p-b-catenin. NC, KYSE450
lls in which NKD2 has been knocked down by siRNA.
1922 Cao et al Journal of Thoracic Oncology Vol. 11 No. 11NKD2 inhibits Wnt signaling in human esophageal can-
cer. To further validate the role of NKD2 on the Wnt
signaling pathway, an siRNA knockdown technique was
used. The expression levels of b-catenin, c-myc, and
cyclinD1 were increased and the level of phospho-b-
catenin was reduced after knockdown of NKD2 in
KYSE450 cells (Fig. 5B). These results suggest that NKD2
represses proliferation of esophageal cancer cells by
inhibiting Wnt signaling.
We further evaluated the expression of phospho-b-
catenin in available samples from 30 cases of primary
esophageal cancer by IHC analysis. The expression levels
of phospho-b-catenin were correlated with the expres-
sion levels of NKD2 in human esophageal cancer, with a
correlation coefﬁcient of 0.798 (p < 0.001 [Fig. 5C]).NKD2 Suppresses Tumor Growth in Esophageal
Cancer Cell Xenograft Mice
To further validate the effects of NKD2 in esophageal
cancer in vivo, KYSE150 cell xenograft mouse models in
which NKD2 was unexpressed and reexpressed, as well
as KYSE450 cell xenograft mouse models in which NKD2
was highly expressed and knocked down, were used
(Fig. 6A). The mean tumor volume was 345.12 ± 18.42
mm3 in KYSE150 cells in which NKD2 was unexpressed
and 96.78 ± 17.29 mm3 in KYSE150 cells in which NKD2
was reexpressed. The tumor volume was signiﬁcantly
smaller in KYSE150 cell xenograft mice in which NKD2
was reexpressed compared with in KYSE150 cell xeno-
graft mice in which NKD2 was unexpressed (p < 0.001).
The tumor volumes were 68.62 ± 7.39 mm3 in KYSE450
cells in which NKD2 was expressed and 113.38 ± 17.31
mm3 in KYSE450 cells xenograft mice in which NKD2
was knocked down. The tumor volume was signiﬁcantly
smaller in KYSE450 cell xenograft mice in which NKD2
was expressed compared with in KYSE450 cell xenograft
mice in which NKD2 was knocked down (p < 0.001
[Fig. 6A and B]). The tumor weights were 220.62 ± 28.51
mg in KYSE150 cell xenograft mice in which NKD2 was
unexpressed and 22.35 ± 5.19 mg in KYSE150 cell
xenograft mice in which NKD2 was reexpressed. The
tumor weight was signiﬁcantly lower in KYSE150 cell
xenograft mice in which NKD2 was reexpressed than in
KYSE150 cell xenograft mice in which NKD2 was unex-
pressed (p < 0.001). The tumor weights were 13.77 ±
5.40 mg in KYSE450 cell xenograft mice in which NKD2
was expressed and 56.12 ± 11.86 mg in KYSE450 cell
xenograft mice in which NKD2 was knocked down. The
tumor weight was signiﬁcantly lower in KYSE450 cell
xenograft mice in which NKD2 was highly expressed
than in KYSE450 cell xenograft mice in which
NKD2 was knocked down (p < 0.001 [Fig. 6C]). To
further validate whether NKD2 inhibits Wnt signalingin vivo, the expression levels of NKD2, b-catenin, and
phospho-b-catenin were detected by IHC staining. The
levels of phospho-b-catenin were increased and the
levels of b-catenin were reduced in NKD2-expressing
esophageal cancer cell xenografts (Fig. 6D). These re-
sults suggest that NKD2 suppresses esophageal cancer
cell growth by inhibiting Wnt signaling in vivo.Discussion
NKD2 was reported to be rarely mutated in human
ESCC.47,48 In our study, no mutations were found in nine
esophageal cancer cell lines and 154 patients with ESCC.
We demonstrated that NKD2 is frequently methylated in
human ESCC and that expression of NKD2 is regulated
by promoter region methylation. These results are sup-
ported by data from The Cancer Genome Atlas.49 Both
DNA methylation and NKD2 expression were analyzed in
tissue from 185 cases of esophageal cancer. The pro-
moter region methylation was inversely associated with
NKD2 expression in esophageal cancer (R ¼ –0.34, p <
0.0001 [Supplementary Fig. 2]). NKD2 methylation is
associated with TNM stage and lymph node metastasis,
suggesting that NKD2 methylation may serve as a poor
prognostic marker in human ESCC. In regard to infor-
mation limitations, we did not analyze the inﬂuence of
smoking and drug consumption in NKD2 methylation.
Our further studies revealed that NKD2 inhibits esoph-
ageal cancer cell proliferation and colony formation and
induces G1/S checkpoint arrest. In addition, NKD2 sup-
presses esophageal cancer cell migration and invasion.
These results demonstrate that NKD2 is involved in
progression and metastasis of esophageal cancer. The
role of NKD2 in suppression of esophageal cancer
growth was validated by an esophageal cancer cell
xenograft model in vivo.
We further explored the mechanism by which NKD2
suppresses progression and metastasis of esophageal
cancer. NKD2 impedes ESCC metastasis by down-
regulating MMP2, MMP7, and MMP9 expression, and it
suppresses ESCC growth by inhibiting Wnt signaling.
Degradation of the ECM and destruction of the basement
membrane by cancer cells are important processes for
direct invasion. There are three kinds of enzymes that
effectively degrade the ECM: MMPs, serine proteinases,
and cysteine proteinases. MMPs are known to play
important roles in ECM remodeling during the process of
tumor invasion and metastasis. The expression of MMPs
was reported to be associated with tumor invasion and
lymph node metastasis in ESCC.50–52 Our results
demonstrate that the expression levels of NKD2 were
negatively correlated with the expression levels of MMPs
both in vitro and in vivo. These results suggest that
NKD2 suppresses ESCC metastasis by inhibiting MMPs.
Figure 6. Naked cuticle homolog 2 (NKD2) suppresses esophageal cancer cell growth in xenograft mice. (A) Representative
burdened nude mice with NKD2 reexpressed and unexpressed in KYSE150 cells and NKD2 expressed and knocked down in
KYSE450 cells. The tumor locations are shown by red arrowhead. (B) Subcutaneous tumor growth curves for xenograft mice
burdened with KYSE150 cells in which NKD2 is unexpressed and reexpressed and KYSE450 cells is which NKD2 is expressed and
knocked down at different times (***p < 0.001). (C) Tumor weight in nude mice at the 24th day after inoculation with KYSE150
cells in which NKD2 is unexpressed and reexpressed and KYSE450 cells in which NKD2 is expressed and knocked down. Bars
indicate mean of six mice (***p < 0.001). (D) Representative photographs of immunohistochemical analysis for NKD2,
b-catenin, and p-b-catenin in xenografts. Staining of NKD2 and p-b-catenin was found in KYSE150 cell xenografts in which
NKD2 is reexpressed. Staining of total b-catenin was reduced in KYSE150 cell xenografts in which NKD2 is reexpressed.
Magniﬁcation: 400. NC, KYSE450 cells in which NKD2 is highly expressed; SiNKD2, KYSE450 cells in which NKD2 has been
knocked down by small interfering RNA.
November 2016 NKD2 Inhibits Wnt Signaling in ESCC 1923The Wnt signaling pathway is conserved in various
organisms, and it plays important roles in develop-
ment and cellular proliferation and differentiation.
Wnt signaling regulates various processes that are
important for cancer development, including tumor
initiation, progression, and metastasis.53 Wnt signaling issuggested to inhibit b-catenin phosphorylation, thus
inducing the accumulation of cytosolic b-catenin. Then,
b-catenin is translocated into the nucleus, where it
stimulates the expression of Wnt/b-catenin–responsive
genes, including myc and cyclinD1.54–58 The c-myc proto-
oncogene (myc), a Wnt/b-catenin target gene, may
1924 Cao et al Journal of Thoracic Oncology Vol. 11 No. 11promote cell cycle progression.59,60 In most circum-
stances, cyclin D associates with Cdk4 and Cdk6 during
early G1 phase.61 In this study, we found that NKD2
represses proliferation of esophageal cancer cells by
inhibiting Wnt signaling in human esophageal cancer
cells both in vitro and in vivo when xenograft mouse
models are used. In human primary esophageal cancer,
the expression levels of phospho-b-catenin were corre-
lated with the expression levels of NKD2. The afore-
mentioned results strongly suggest that NKD2 represses
esophageal cancer growth by inhibiting Wnt signaling in
human esophageal cancer.
At the time of diagnosis, more than 50% of patients
with esophageal cancer have metastatic disease.62
Although there are many approaches to treating meta-
static disease, the overall survival remains poor. Un-
derstanding the molecular events in ESCC may improve
therapeutic strategies.63,64 Our ﬁndings provide more
clues for epigenetic-based personalized medicine in
esophageal cancer.
Conclusion
NKD2 is frequently methylated in human esophageal
cancer, and the expression of NKD2 is regulated by
promoter region methylation. Methylation of NKD2 is
associated with TNM stage and lymph node metastasis.
NKD2 suppresses growth of human esophageal cancer
by inhibiting Wnt signaling.
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